Crohn’s Disease | Treatment Algorithms: Claims Data Analysis | Pediatric | US | 2025

Children with Crohn’s disease (CD) have a more-complicated disease course than that of adult patients. Historically, treatment of pediatric CD would begin with safe, albeit often less-efficacious, conventional agents (e.g., 5-ASAs) and then progress to more-potent drugs, such as biologics and/or immunosuppressants. This scenario has changed, and more physicians are now prescribing biologics, especially tumor necrosis factor (TNF)-alpha inhibitors (e.g., infliximab, adalimumab), as first-line therapy for both newly diagnosed and recently treated pediatric CD patients. Non-TNF biologics, including Takeda’s Entyvio, Johnson & Johnson Innovative Medicine’s Stelara, and oral targeted therapies such as AbbVie’s Rinvoq, may be prescribed as well, particularly after anti-TNF failure.

QUESTIONS ANSWERED

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed pediatric CD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed pediatric CD patients?
• How have Entyvio and Rinvoq been integrated into the treatment algorithm, and what is their source of business?
• What percentage of pediatric CD patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
• What percentage of pediatric CD patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

• Understand patient flow between lines of therapy.
• Evaluate your brand share against competitors.
• Accurately assess your source of business.

Markets covered: United States

Key drugs: Entyvio, Stelara, Rinvoq, Remicade and infliximab biosimilars, Humira and adalimumab biosimilars, Skyrizi

Key feature: Dashboard featuring interactive visuals, easy navigation, and expanded analyses